|
|
Volumn 5, Issue 7, 2015, Pages 684-685
|
|
Expanding the Reach of Anti-PD-1 Therapy
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CETUXIMAB;
MONOCLONAL ANTIBODY;
NIVOLUMAB;
PDCD1 PROTEIN, HUMAN;
PEMBROLIZUMAB;
PROGRAMMED DEATH 1 RECEPTOR;
ANTAGONISTS AND INHIBITORS;
ART;
CARCINOMA, SQUAMOUS CELL;
CLINICAL STUDY;
GENETICS;
HEAD AND NECK NEOPLASMS;
HUMAN;
LIVER NEOPLASMS;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC AGENTS;
CARCINOMA, SQUAMOUS CELL;
CETUXIMAB;
CLINICAL STUDIES AS TOPIC;
HEAD AND NECK NEOPLASMS;
HUMANS;
LIVER NEOPLASMS;
PROGRAMMED CELL DEATH 1 RECEPTOR;
SURVIVAL ANALYSIS;
TREATMENT OUTCOME;
|
|
EID: 84979799674
PISSN: None
EISSN: 21598290
Source Type: Journal
DOI: 10.1158/2159-8290.CD-NB2015-082 Document Type: Article |
|
Times cited : (5)
|
|
References (0)
|